Alector Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2020 / 03:40PM GMT
Neena Marie Bitritto-Garg - Citigroup Inc., Research Division - VP & Analyst

All right. So good morning, everyone. Thank you for joining Citi's 15th Annual Biopharma Conference. I'm Neena Bitritto-Garg. I'm one of the Smid cap biotech analyst here at Citi. For our fireside chat, I'm pleased to be joined by the team from Alector. I have with me today Shehnaaz Suliman, President and COO; Robert Paul, Chief Medical Officer; and Sabah Oney, Chief Business Officer.

So just to start off, Shehnaaz, if you want to talk a little bit about just kind of the concept of neuroimmunology and how it's differentiated from some of the previous approaches that have been taken in neurodegenerative diseases, that would be great.

Questions and Answers:

Shehnaaz Suliman - Alector, Inc. - President & COO

Thank you, Neena, and it's great to be with everyone today. We're pioneering a completely new approach to treating brain disorders, which we call immuno-neurology, which integrates immunology and neuroscience and genetics to develop therapeutics
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot